Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of BSB-1001 in Patients Undergoing HLA-Matched AlloHSCT for AML, ALL or MDS
NCT06704152Phase 2Terminated
- Sponsor
- BlueSphere Bio
- Start
- Feb 2025
- Primary completion
- Sep 2026
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of BSB-1001 in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), sponsored by BlueSphere Bio. Started Feb 2025; status: terminated.
02
Drugs
BSB-1001
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06704152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06704152.